Abstract
The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell adhesion, is associated with the metastatic potential of solid tumors and is required for maintenance of cell viability by preventing apoptosis. LRP/LR acts as a receptor for viruses such as Sindbis virus, Venezuelean Equine Encephalitis (VEE) virus, Adeno-associated-viruses (AAV) and Dengue Virus, the latter causing 50 to 100 million infections in humans per year. LRP/LR acts further as a receptor for prions and represents a multifunctional protein subcellularly located to the nucleus, the cytoplasm and the cell surface. The receptor represents an alternative target for therapy of viral infections, cancer and prion disorders and might play additional roles in further neurodegenerative diseases such as Alzheimers disease. The species barrier in prion disorders might be at least in part determined by the presence of LRP/LR in enterocytes of the intestinal epithelium. Anti- LRP/LR antibodies, siRNAs directed against LRP mRNA, polysulfated glycanes such as pentosan polysulfate and heparan mimetics and LRP decoy mutants are promising tools for blocking or downregulating the receptor and may represent alternative therapeutics for the treatment of prion disorders, Alzheimers Disease and metastatic cancer.
Keywords: 37kDa/67kDa laminin receptor LRP/LR, prion, protein, PrP, neurodegenerative disease, HSPG, pentosan polysulfate, antibody, siRNA, species barrier
Infectious Disorders - Drug Targets
Title: LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Volume: 9 Issue: 1
Author(s): Karen Vana, Chantal Zuber, Heike Pflanz, Dominika Kolodziejczak, Georgeta Zemora, Ann-Katrin Bergmann and Stefan Weiss
Affiliation:
Keywords: 37kDa/67kDa laminin receptor LRP/LR, prion, protein, PrP, neurodegenerative disease, HSPG, pentosan polysulfate, antibody, siRNA, species barrier
Abstract: The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell adhesion, is associated with the metastatic potential of solid tumors and is required for maintenance of cell viability by preventing apoptosis. LRP/LR acts as a receptor for viruses such as Sindbis virus, Venezuelean Equine Encephalitis (VEE) virus, Adeno-associated-viruses (AAV) and Dengue Virus, the latter causing 50 to 100 million infections in humans per year. LRP/LR acts further as a receptor for prions and represents a multifunctional protein subcellularly located to the nucleus, the cytoplasm and the cell surface. The receptor represents an alternative target for therapy of viral infections, cancer and prion disorders and might play additional roles in further neurodegenerative diseases such as Alzheimers disease. The species barrier in prion disorders might be at least in part determined by the presence of LRP/LR in enterocytes of the intestinal epithelium. Anti- LRP/LR antibodies, siRNAs directed against LRP mRNA, polysulfated glycanes such as pentosan polysulfate and heparan mimetics and LRP decoy mutants are promising tools for blocking or downregulating the receptor and may represent alternative therapeutics for the treatment of prion disorders, Alzheimers Disease and metastatic cancer.
Export Options
About this article
Cite this article as:
Vana Karen, Zuber Chantal, Pflanz Heike, Kolodziejczak Dominika, Zemora Georgeta, Bergmann Ann-Katrin and Weiss Stefan, LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer, Infectious Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/1871526510909010069
DOI https://dx.doi.org/10.2174/1871526510909010069 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective
Current Analytical Chemistry Mathematical Models for the Management of Helminth Parasites: From Biological Processes to the Evolution of Anthelmintic Resistance
Anti-Infective Agents in Medicinal Chemistry Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Biotechnological Approaches for Control of Listeria monocytogenes in Foods
Current Biotechnology Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Structural Disorder within the Measles Virus Nucleoprotein and Phosphoprotein
Protein & Peptide Letters Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Global Warming Favors Pathogenicity of the Brain-Eating Amoebae
Anti-Infective Agents Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews